Scarica l'app Stockscreener
2.52
2.44%
0.06
Dopo l'orario di chiusura:
2.42
-0.10
-3.97%
Precedente Chiudi:
$2.46
Aprire:
$2.44
Volume 24 ore:
234.27K
Relative Volume:
0.49
Capitalizzazione di mercato:
$66.79M
Reddito:
-
Utile/perdita netta:
$-24.88M
Rapporto P/E:
-1.6987
EPS:
-1.4835
Flusso di cassa netto:
$-24.98M
1 W Prestazione:
+1.20%
1M Prestazione:
+6.33%
6M Prestazione:
+1.61%
1 anno Prestazione:
+52.73%
Intervallo 1D:
$2.44
$2.56
Intervallo di 1 settimana:
$2.4101
$2.71
Portata 52W:
$1.11
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Nome
Annovis Bio Inc
Settore
Industria
Telefono
484-875-3192
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.52 | 66.79M | 0 | -24.88M | -24.98M | -1.4835 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Aggiornamento | Maxim Group | Hold → Buy |
| 2023-12-29 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
Annovis Bio Inc Borsa (ANVS) Ultime notizie
Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program - Stock Titan
Annovis Bio’s Buntanetap: Advancing Clinical Development for Alzheimer’s and Parkinson’s Disease with Novel Multi-Targeted Approach 33 - Minichart
Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026 - TradingView
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ANVS|Annovis Bio Inc|Price:2.490|Chg%:-0.09 - TradingKey
Published on: 2026-03-11 14:44:25 - baoquankhu1.vn
Annovis Bio to present buntanetap clinical data at AD/PD 2026 conference - MSN
Annovis Bio to Present Buntanetap Clinical Data at AD/PD 2026 Conference - MyChesCo
Support Test: Is Annovis Bio Inc. stock technically oversold2026 WrapUp & Technical Confirmation Trade Alerts - baoquankhu1.vn
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia - MSN
Momentum Shift: What makes Annovis Bio Inc stock attractive todayM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Annovis Bio Stock Price Drops 8.5%What's Next? - National Today
Annovis Bio (NYSE:ANVS) Stock Price Down 8.5%What's Next? - MarketBeat
Annovis CEO eyes spring breakthrough for Alzheimer’s drug - Longevity.Technology
Annovis Announces Two Presentations at the AD/PD 2026 International Conference - Bitget
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - The Manila Times
AI Stocks: Will Annovis Bio Inc. benefit from rising consumer demandTrade Exit Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze? - AD HOC NEWS
ANVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Annovis nears FDA threshold for Alzheimer's drug as CEO eyes spring milestone - The Business Journals
Tech Rally: Whats the analyst consensus on Annovis Bio Inc2025 Buyback Activity & AI Powered Market Entry Ideas - baoquankhu1.vn
Annovis Bio (ANVS): Alzheimer’s Data, Cash Burn and Why Traders Are Split - AD HOC NEWS
Should you avoid Annovis Bio Inc. stock right nowEarnings Recap Summary & Weekly Setup with ROI Potential - mfd.ru
Trading Action: Will Annovis Bio Inc. benefit from seasonalityJuly 2025 Weekly Recap & Technical Pattern Based Signals - mfd.ru
Is Annovis Bio Inc. a defensive stockJuly 2025 Final Week & Safe Capital Growth Trade Ideas - mfd.ru
Aug Analyst Calls: Will Annovis Bio Inc benefit from seasonalityQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Rate Hike: Can ADSE keep up with sector leadersJuly 2025 Setups & Verified Entry Point Detection - baoquankhu1.vn
Malvern-based Annovis continues phase 3 Alzheimer’s trial after safety review - MSN
Malvern-Based Annovis Continues Phase 3 Alzheimer’s Trial After Safety Review - MyChesCo
Will Annovis Bio Inc. stock rally after Fed decisionsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - mfd.ru
Can Annovis Bio Inc. disrupt its industryJuly 2025 Institutional & Real-Time Volume Triggers - mfd.ru
ANVS Should I Buy - Intellectia AI
Guidance Update: Will Annovis Bio Inc. stock recover after earningsJuly 2025 Highlights & Low Risk Growth Stock Ideas - mfd.ru
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod - TipRanks
Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView
Annovis Bio Receives Positive Safety Recommendation from DSMB for Buntanetap in Alzheimer's Phase 3 Trial - Quiver Quantitative
Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease. - Bitget
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease - ChartMill
Annovis Bio (NYSE:ANVS) Shares Down 1%Here's Why - MarketBeat
Is Annovis Bio Inc. stock forming a triangle patternJuly 2025 EndofMonth & Momentum Based Trading Ideas - mfd.ru
Is Annovis Bio Inc. part of any major indexEntry Point & Long Hold Capital Preservation Tips - mfd.ru
CEO Moves: Should you avoid Annovis Bio Inc. stock right nowJuly 2025 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Can Annovis Bio Inc. deliver consistent dividendsJuly 2025 Technicals & Reliable Entry Point Alerts - mfd.ru
How Annovis Bio Inc. stock performs during Fed tightening cyclesJuly 2025 News Drivers & Real-Time Stock Price Movement Reports - mfd.ru
Highs Report: Should you avoid Annovis Bio Inc stock right nowQuarterly Investment Review & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Stock Market Recap: Will Annovis Bio Inc. benefit from rising consumer demand2025 Support & Resistance & Reliable Momentum Entry Alerts - baoquankhu1.vn
Portfolio Recap: Will APA Corporation outperform its industry peersWeekly Risk Summary & High Yield Stock Recommendations - baoquankhu1.vn
Annovis Bio Hosts Regulation FD Investor Information Webinar - TipRanks
Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials - TradingView
Annovis Bio Inc Azioni (ANVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):